Determining Molecular Drivers of Radiation Dermatitis

Mayo Clinic

Status: Active, not recruiting

Conditions: Breast Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT04764682

19-005445

Details and patient eligibility

About

This study is being conducted to address key gaps in current knowledge and set the stage for rational design of strategies to prevent (pre-exposure to radiation), mitigate (post-exposure to radiation before overt signs/symptoms appear), and/or treat (post-onset of signs/symptoms) radiation dermatitis (itchy, dry skin or a rash on swollen, reddened skin).

Enrollment: 20 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients receiving standard-of-care postoperative radiation therapy (2-2.7 Gy per fraction) to the breast and/or chest wall for breast cancer treatment.
• Tissue diagnosis of breast cancer.
• Age > 18 years
• Signed informed consent.
• Complete blood count within normal limits within the preceding 2 weeks.

Exclusion criteria

• Induction chemotherapy or biologic therapy
• Concurrent chemotherapy or biologic therapy
• Autoimmune disease with skin manifestations - psoriasis, dermatomyositis, scleroderma, eczema, polymyositis
• Allergy to lidocaine anesthesia
• Known bleeding diathesis (anticoagulation with warfarin, coagulation/bleeding disorders, vitamin C or K deficiency, thrombocytopenia)
• History of keloids or easy scarring